Investors are encouraged to contact Kaplan Fox before the lead attorney’s deadline on March 4, 2025. Investing.com
NEW YORK – January 11, 2025 (NEWMEDIAWIRE) – Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics (NASDAQ: ), Inc . (Revance or the Company) (NASDAQ: RVNC ) on behalf of investors who purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the Class Period).
CLICK HERE TO JOIN THE CASE
If you are an investor in Revance and have suffered losses, you can CLICK HERE to contact us. You can also contact Kaplan Fox by emailing pmayer@kaplanfox.com or calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed class, you may move the court no later than March 4, 2025 to be the lead plaintiff for the putative class. If you have losses, we encourage you to contact us to learn more about the Attorney General process.
Revance is a biotechnology company and distributor of certain dermal filler products under an exclusive distribution agreement with Teoxane SA.
On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories (Crown). Under the terms of the agreement, the press release indicated that Crown will initiate an offer to purchase all outstanding shares of Revances common stock for $6.66 per share (the Tender Offer).
Then on September 23, 2024, Revance disclosed that it had received notice to correct alleged material violations, including violations of maximum intermediate inventory levels and required efforts to promote and sell Teoxane products, under the company’s exclusive distribution agreement with Teoxane SA. Due to the dispute with Teoxane, the Company has advised that the Crowns Tender Offer has been postponed until at least 4 October 2024.
Following this news, Revance’s stock price fell $0.445 per share, or 7.66%, to $5.365 per share on September 23, 2024.
Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement and that on December 12, 2024, Crown would initiate an offer to purchase all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the initial purchase price.
Following this news, Revance’s stock price fell $0.79 per share, or 20.68%, to $3.03 per share on December 9, 2024.
The lawsuit alleges, among other things, that during the Lecture Period, the defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the above has exposed the Company to an increased risk of litigation, as well as monetary and reputational damages; and (iii) all of the foregoing increased the risk that the Tender Offer would be delayed and/or modified.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and results clients demand. Through litigating cases at the federal and state levels, Kaplan Fox has successfully shaped the law by making many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you can visit our website at www.kaplanfox.com.
This press release may be considered solicitor advertising in some jurisdictions under applicable law and ethical rules.
If you have any questions about this Notice, your rights or interests, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
See the original release at www.newmediawire.com
Copyright 2025 JCN Newswire. All rights reserved.
